A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Reverse Transcriptase Inhibitors - Trial NCT05839639
Access comprehensive clinical trial information for NCT05839639 through Pure Global AI's free database. This Phase 2 trial is sponsored by Huahui Health and is currently Not yet recruiting. The study focuses on Chronic Hepatitis B. Target enrollment is 73 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Huahui Health
Timeline & Enrollment
Phase 2
Oct 09, 2021
May 30, 2023
Primary Outcome
Proportion of participants achieving sustained viral response,Changes from baseline in serum HBsAg levels
Summary
This is a multicenter, randomized, controlled Phase IIa study of HH-003 injection, HH-003
 injection is a monoclonal antibody targeting Hepatitis B virus. This study aims to evaluate
 the antiviral activity and safety in subjects with with HBeAg-negative Chronic Hepatitis B
 treated with nucleos(t)ide reverse transcriptase inhibitors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05839639
Non-Device Trial